Monover (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monover, is an iron supplement presented as an injection for intravenous use. It treats iron deficiency anemia in patients who require rapid iron repletion and cannot tolerate oral iron therapy.

GNH USA supplies Monover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Monover is an intravenous iron preparation used to correct iron deficiency anemia and related conditions.

Iron deficiency anemia: restores hemoglobin and ferritin levels in patients with inadequate iron stores. Chronic kidney disease‑associated anemia: improves iron availability for erythropoiesis in CKD patients. Perioperative anemia: reduces the need for allogeneic blood transfusion during and after surgery.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Infusion site pain: local discomfort at the injection site. - Dizziness: temporary light‑headedness. - Flushing: brief skin redness. - Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decrease. - Acute respiratory distress: sudden breathing difficulty. - Iron overload: excessive iron accumulation. - Cardiac arrest: rare but life‑threatening event. - Severe injection site reactions: necrosis or ulceration.

Before initiating therapy, clinicians should evaluate iron status and monitor response.

Assess iron deficiency: confirm low ferritin or transferrin saturation before use. Monitor hemoglobin and ferritin: check levels periodically during treatment. Administer under medical supervision: ensure facilities for managing hypersensitivity reactions. Avoid in known hypersensitivity: do not give to patients with previous reaction to ferric derisomaltose. Caution with active infection: defer treatment until infection is controlled. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ferric derisomaltose may interact with other agents that affect iron metabolism or cardiovascular stability.

Major Interactions (Avoid): - Concurrent IV iron products: risk of iron overload. - Erythropoiesis‑stimulating agents: may increase iron accumulation. - High‑dose vitamin C: enhances iron absorption, potentially worsening overload.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce iron availability. - Tetracycline antibiotics: chelation may lower efficacy of both drugs. - Levothyroxine: iron can impair absorption; separate dosing times.